Literature DB >> 17199293

(alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.

Jack D Sadowsky1, W Douglas Fairlie, Erik B Hadley, Hee-Seung Lee, Naoki Umezawa, Zaneta Nikolovska-Coleska, Shaomeng Wang, David C S Huang, York Tomita, Samuel H Gellman.   

Abstract

The development of molecules that bind to specific protein surface sites and inhibit protein-protein interactions is a fundamental challenge in molecular recognition. New strategies for approaching this challenge could have important long-term ramifications in biology and medicine. We are exploring the concept that unnatural oligomers with well-defined conformations ("foldamers") can mimic protein secondary structural elements and thereby block specific protein-protein interactions. Here, we describe the identification and analysis of helical peptide-based foldamers that bind to a specific cleft on the anti-apoptotic protein Bcl-xL by mimicking an alpha-helical BH3 domain. Initial studies, employing a fluorescence polarization (FP) competition assay, revealed that among several alpha/beta- and beta-peptide foldamer backbones only alpha/beta-peptides intended to adopt 14/15-helical secondary structure display significant binding to Bcl-xL. The most tightly binding Bcl-xL ligands are chimeric oligomers in which an N-terminal alpha/beta-peptide segment is fused to a C-terminal alpha-peptide segment ((alpha/beta + alpha)-peptides)). Sequence-affinity relationships were probed via standard and nonstandard techniques (alanine scanning and hydrophile scanning, respectively), and the results allowed us to construct a computational model of the ligand/Bcl-xL complex. Analytical ultracentrifugation with a high-affinity (alpha/beta + alpha)-peptide established 1:1 ligand:Bcl-xL stoichiometry under FP assay conditions. Binding selectivity studies with the most potent (alpha/beta + alpha)-peptide, conducted via surface plasmon resonance measurements, revealed that this ligand binds tightly to Bcl-w as well as to Bcl-xL, while binding to Bcl-2 is somewhat weaker. No binding could be detected with Mcl-1. We show that our most potent (alpha/beta + alpha)-peptide can induce cytochrome C release from mitochondria, an early step in apoptosis, in cell lysates, and that this activity is dependent upon inhibition of protein-protein interactions involving Bcl-xL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17199293     DOI: 10.1021/ja0662523

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  52 in total

Review 1.  Targeting recognition surfaces on natural proteins with peptidic foldamers.

Authors:  James W Checco; Samuel H Gellman
Journal:  Curr Opin Struct Biol       Date:  2016-07-05       Impact factor: 6.809

Review 2.  The Bcl-2 apoptotic switch in cancer development and therapy.

Authors:  J M Adams; S Cory
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 3.  Foldamers as versatile frameworks for the design and evolution of function.

Authors:  Catherine M Goodman; Sungwook Choi; Scott Shandler; William F DeGrado
Journal:  Nat Chem Biol       Date:  2007-05       Impact factor: 15.040

Review 4.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 5.  Sophistication of foldamer form and function in vitro and in vivo.

Authors:  Arjel D Bautista; Cody J Craig; Elizabeth A Harker; Alanna Schepartz
Journal:  Curr Opin Chem Biol       Date:  2007-11-07       Impact factor: 8.822

6.  Sequence-based design of alpha/beta-peptide foldamers that mimic BH3 domains.

Authors:  W Seth Horne; Melissa D Boersma; Matthew A Windsor; Samuel H Gellman
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

7.  Beta-peptides with improved affinity for hDM2 and hDMX.

Authors:  Elizabeth A Harker; Douglas S Daniels; Danielle A Guarracino; Alanna Schepartz
Journal:  Bioorg Med Chem       Date:  2009-01-23       Impact factor: 3.641

8.  Molecular basis for Bcl-2 homology 3 domain recognition in the Bcl-2 protein family: identification of conserved hot spot interactions.

Authors:  Gautier Moroy; Elyette Martin; Annick Dejaegere; Roland H Stote
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

9.  Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the pro-survival Bcl-2 proteins.

Authors:  Erinna F Lee; Anna Fedorova; Kerry Zobel; Michelle J Boyle; Hong Yang; Matthew A Perugini; Peter M Colman; David C S Huang; Kurt Deshayes; W Douglas Fairlie
Journal:  J Biol Chem       Date:  2009-09-10       Impact factor: 5.157

10.  α-Helix mimicry with α/β-peptides.

Authors:  Lisa M Johnson; Samuel H Gellman
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.